Asahi Kasei Pharma, CoTherix Conclude Licensing Agreement for Fasudil, Rho-kinase Inhibitor.Tokyo, Japan, July 4, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Asahi Kasei Pharma and CoTherix have entered into a licensing agreement for oral and inhaled formulations of fasudil, a rho-kinase inhibitor developed by Asahi Kasei Pharma. Under the agreement terms announced June 29, Asahi Kasei Parma will license CoTherix of California to develop and sell fasudil in North America and Europe. CoTherix plans to introduce the agent for the treatments of angina (an oral formulation) and pulmonary hypertension Pulmonary Hypertension Definition Pulmonary hypertension is a rare lung disorder characterized by increased pressure in the pulmonary artery. The pulmonary artery carries oxygen-poor blood from the lower chamber on the right side of the heart (right (both oral and inhaled formulations). CoTherix will make an upfront payment of $8.75 million, and development and revenue milestone payments and royalties on future products to Asahi Kasei Pharma. Currently, fasudil is available in Japan under the trade name of Eril Inj.S. for the treatment of cerebrovascular cer·e·bro·vas·cu·lar adj. Relating to the blood supply to the brain, particularly with reference to pathological changes. cerebrovascular pertaining to the blood vessels of the cerebrum or brain. spasm and cerebral ischemia cerebral ischemia, n the reduction or loss of oxygen to the cerebrum; prolonged ischemia may lead to cerebral infarction. after subarachnoid hemorrhage. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion